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ABSTRACT
Introduction: The EDITION development pro-
gram confirmed that insulin glargine 300 U/mL
(Gla-300) provides comparable glycemic control
to insulin glargine 100 U/mL (Gla-100) but with
lower hypoglycemia risk. Our study aimed to
evaluate the effectiveness of Gla-300 in every-
day practice.
Methods: This one-arm, non-interventional
study included patients with type 2 diabetes
who were switched to Gla-300-based basal-bolus
therapy (BBT) and followed for 6 months. Indi-
cations for switching included inadequate gly-
cemic control and/or hypoglycemic events with
the previous regimen.
Results: Overall 229 patients were included,
with mean age of 60.9 years. All glycemic vari-
ables improved between baseline and 6 months
significantly (mean ± standard deviation [SD]
hemoglobin A1c [HbA1c] from 8.9 ± 1.5% to
7.5 ± 1.1%, fasting blood glucose from
9.5 ± 3.1 mmol/L to 7.0 ± 2.1 mmol/L, post-
prandial blood glucose from 12.0 ± 3.8 mmol/L
to 8.9 ± 2.5 mmol/L). Gla-300 doses were
increased and mealtime insulin doses were
unchanged. Rates of both non-severe and severe
hypoglycemic events decreased significantly
compared to pre-study and 6-month follow-up
periods. Patients switched because of elevated
HbA1c had higher baseline HbA1c and greater
decrease in HbA1c paralleled with increase in
insulin doses compared to those switched
because of hypoglycemia.
Conclusions: In day-to-day practice, switching
from human insulin to Gla-300-based BBT
resulted in significant improvement in glycemic
control and decrease in hypoglycemia risk.
Keywords: Basal-bolus treatment; Diabetes
mellitus type 2; Insulin glargine 300 U/mL
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Key Summary Points
Insulin glargine 300 U/mL was shown to
improve glycemic control equally as well
as insulin glargine 100 U/mL but was
associated with lower risk of
hypoglycemia.
This non-interventional trial was initiated
to investigate the effectiveness of insulin
glargine 300 U/mL in subgroups of
patients with type 2 diabetes specified in
the Hungarian reimbursement rules.
When switching from human insulin
treatment, insulin glargine 300 U/mL
based analogue basal-bolus regimen
resulted in significant improvement in
glycemic control and could be applied
safely with decreased risk of
hypoglycaemia.
Insulin glargine 300 U/mL performed well
in subgroup of patients switched due to
inadequate glycemic control and in
subgroup switched due repeated or serious
hypoglycemic events.
INTRODUCTION
The joint task force of the American Diabetes
Association (ADA) and the European Association
for the Study of Diabetes (EASD) updated its
consensus on the management of type 2 diabetes
(T2DM) in 2018 [1] reflecting both the epidemi-
ologic and healthcare impact of the condition
and the increasingly complex treatment algo-
rithm that physicians need to apply in a person-
alized way at individual patient level. Echoing the
consensus statements in 2012 and 2015 [2, 3],
lifestyle modification composes the foundation of
treatment followed by metformin monotherapy;
then, in case of inadequate glycemic control,
metformin can be supplemented with several
other drugs, including basal insulin.
Long-acting basal insulin (BI) analogues have
successfully been used for almost two decades.
Insulin glargine 100 U/mL (Gla-100), the first
member of this new drug class, was approved in
2000 [4]. Its clinical program demonstrated its
prolonged effect compared to human BI, its
relatively peak-less concentration–time profile,
and consequently lower risk of hypoglycemia
[4] associated with its use. As a result of the
residual limitation of their duration of action to
reliably cover 24 h, first-generation BI analogues
have been further improved by manufacturers
which resulted in the development of second-
generation BI analogues, insulin glargine 300 U/
mL (Gla-300) and insulin degludec.
In the EDITION clinical trial program (EDI-
TION 1, 2, and 3 trials [5–7]), which included
patients with T2DM, Gla-300 was compared to
Gla-100 as part of different treatment regimens.
In all these studies, the glycemic control (indi-
cated by the levels of hemoglobin A1c [HbA1c])
improved equally in both study arms. From a
safety perspective, the EDITION studies pro-
vided evidence that Gla-300 compared to Gla-
100 was associated with lower risk of hypo-
glycemia, probably due to its improved phar-
macokinetic and pharmacodynamics (PK/PD)
properties [8, 9]. The 6-month patient-level
meta-analysis of EDITION 1, 2, and 3 trials [10]
confirmed the results of the individual trials,
while the analysis of the 12-month data
revealed a modest but statistically significant
difference in HbA1c as well in favor of Gla-300
[11]. The lower risk of hypoglycemic events
with Gla-300 was detected not only during
highly controlled randomized clinical trials but
also the analysis of data of patients with T2DM
from the Optum Humedica database showed
[12] that Gla-300 was associated with lower
event rate of severe hypoglycemia when com-
pared to first-generation BI analogues (Gla-100
and insulin detemir). This analysis also con-
firmed that the lower rate of severe hypo-
glycemia was not associated with worse
glycemic control.
Insulin glargine 300 U/mL (Gla-300) was
launched in Hungary in 2016 and has been
mainly used as part of basal-bolus therapy (BBT)
as a result of restricted national reimbursement
conditions. For patients with T2DM, it can be
prescribed with 50% patient co-payment in
basal-only therapy or with 100%
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reimbursement as part of BBT. However, even in
BBT, analogue insulins can be initiated as sec-
ond-line options when (1) targeted glycemic
control (i.e., HbA1c\ 8%) could not be
achieved after at least 3 months on human BBT;
or (2) the patient had at least three documented
hypoglycemic events per month during a
3-month human BBT period; or (3) the patient
had at least one severe hypoglycemic event (an
event that required third-party assistance) on
human BBT. In addition to treatment initiation
rules, a stopping rule for analogue insulin
treatment has also been introduced. Gla-300
and other BI analogues could only be prescribed
beyond 1-year treatment period if at least two
HbA1c levels of below 8.0% have been mea-
sured during analogue BBT over the course of
12 months.
As there was no real-life experience with Gla-
300 in Hungary, a non-interventional trial was
initiated in 2016 to investigate its effectiveness
(impact on glycemic control and hypoglycemia
risk) in everyday practice in T2DM. The included
patients met the Hungarian reimbursement rules,
i.e., were switched from human BBT to Gla-300-
based analogue BBT (on the basis of payer criteria
defined above). The patients were administered
insulin glulisine as mealtime insulin.
METHODS
This prospective, one-arm, non-interventional
study included patients with T2DM, aged
18–80 years, who were switched to insulin glar-
gine 300 U/mL (Gla-300) plus insulin glulisine
treatment at the time of inclusion. The patients
had to meet at least one of the reimbursement
criteria detailed in the ‘‘Introduction’’ section.
During the 6-month study period, the
patients were followed according to local prac-
tice. Clinical parameters and laboratory results
routinely collected in day-to-day care were
recorded, with study-related visits at baseline
(i.e., at enrollment—visit 1), at 3 months
(visit 2), and at 6 months (visit 3), according to
everyday practice. At baseline, recorded data
included demographics, treatment and medical
history, hypoglycemic events reported during
the last 3 months before the switch to analogue
treatment, current antidiabetic (insulin and oral
antidiabetes agent [OAD]) treatment; reason
(indication) for switching to analogue basal-
bolus regimen; and glycemic parameters
including target ranges for HbA1c, fasting
plasma glucose (FPG), and postprandial blood
glucose (PPG). At follow-up visits, current gly-
cemic variables, body weight, current OAD
treatments, insulin doses, and self-reported
hypoglycemic and other safety events were
recorded; fasting blood glucose and PPG levels
were self-monitored by patients. The safety
analysis included the patients who had at least
one follow-up physician contact. The efficacy
analysis included the patients who had avail-
able HbA1c values both at baseline and at
6 months. Additional subgroup analyses were
conducted comparing patient subgroups
according to their switching indication, i.e.,
inadequate glycemic control or hypoglycemic
events on previous human insulin regimen.
Those patients who were switched because of
more than one indication were excluded from
these subgroup analyses.
Normal distribution of continuous variables
was investigated with a quantile–quantile (QQ)
plot. Paired and two-sample t tests were applied
for group comparisons and for time-dependent
changes, respectively. All analyses were run in
IBM SPSS Statistics 19.0.
The study (named ‘‘Toujeo-6M’’) conformed
to the Helsinki Declaration of 1964, as revised
in 2013, and was approved by Hungarian
National Institute of Pharmacy and Nutrition
(registration code OGYI/44755-7/2015) and
received national ethical approval as well. All
patients gave written informed consent before
any data collection.
RESULTS
Baseline Characteristics
Overall 229 patients were included, of whom
217 patients (94.8%) had at least one follow-up
visit (included in the safety analyses) and 189
(82.5%) had enough data to be included in the
efficacy analyses. In the subgroup analyses (that
excluded patients who were switched because of
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Table 1 Baseline values, human and baseline analogue insulin doses, and individual end-of-study target HbA1c ranges of
the efficacy population
Variable Mean – SD or %
Demographic values and medical history
Age at time of enrollment (years) 60.9 ± 10.4
Male sex (%) 47.1
Age at time of diagnosis of type 2 diabetes (years) 47.5 ± 10.0
Duration of diabetes history at time of enrollment (years) 13.4 ± 7.9
Duration of insulin treatment at time of enrollment (years) 7.4 ± 6.2
Baseline values
HbA1c level (%) 8.9 ± 1.5
Fasting blood glucose level (mmol/L) 9.5 ± 3.1
Postprandial blood glucose level (mmol/L) 12.0 ± 3.8
Body weight (kg) 94.1 ± 18.2
Body mass index (kg/m2) 32.8 ± 5.8
Last daily human basal and prandial insulin doses (just before the analogue switch)
Basal insulin (IU) 30.3 ± 20.1
Prandial insulin (IU) 46.5 ± 24.6
Basal ratio 0.39
Daily insulin doses at baseline
Gla-300 (U) 34.5 ± 16.6
Insulin glulisine (U) 39.7 ± 21.8
Basal ratio 0.47
OAD treatment at baseline (%)
No OAD 46.0
One OAD 49.7
Two OADs 4.2
Distribution of OADs (%)
Metformin 53.4
Gliclazide 0.5
Empagliflozin 3.7
Sitagliptin 0.5
Individual HbA1c-target range specified at baseline (%)
Specified 74.6
\ 7.0% 2.7
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more than one indication), overall 190 patients
could be included in the safety analyses (152
were switched because of inadequate control
and 38 because of hypoglycemic events) and
160 in the efficacy analyses (of whom 128 were
switched because of inadequate control and 32
because of hypoglycemic events).
Baseline characteristics for the efficacy popula-
tion are summarized in Table 1. At baseline,
patients’ mean age was 60.9 ± 10.4 years (± stan-
dard deviation [SD]), mean duration of T2DM was
13.4 ± 7.9 years, and mean treatment duration
with insulinwas 7.4 ± 6.2 years.Theproportionof
male patients was 47.1%. Mean body mass index
(BMI) was 32.8 ± 5.8 kg/m2 at baseline.
Available glycemic parameters indicated
inadequate glycemic control for the enrolled
population. Baseline daily doses of both basal
and prandial analogue insulins were higher
compared to the applied human insulin doses
before switch. The most frequently (58.7%)
specified individual target HbA1c range was
below 8.0% and at least 7.0%. Target HbA1c was
not specified in one-quarter of the patients.
Among patients receiving OAD treatment at
baseline (53.9% in total), 49.7% were receiving
one OAD and 4.2% were receiving two OADs.
The most frequently used OAD was metformin
(53.4%), with empagliflozin (3.7%), glicazide
(0.5%), and sitagliptin (0.5%) being used by a
small proportion of patients.
Efficacy Outcomes, Target Range
Achievement, and Change in Body Weight
The three glycemic variables significantly
decreased by the end of the study (mean ± SD):
HbA1c from 8.9 ± 1.5% to 7.5 ± 1.1%, fasting
blood glucose from 9.5 ± 3.1 mmol/L to
7.0 ± 2.1 mmol/L, and postprandial blood glu-
cose from 12.0 ± 3.8 mmol/L to 8.9 ± 2.5 mmol/
L (Table 2). All of these improvements were sta-
tistically significant already by 3 months. Clini-
cally relevant improvement between 3 and
6 months could be detected in HbA1c levels.
Accordingly, the proportion of patients achieving
different HbA1c target values (i.e., \7% that is
the most commonly specified in guidelines, and
8% that is the cutoff value in the Hungarian
reimbursement rules) continuously increased,
and close to 80% of patients achieved the 8.0%
payer target by 6 months (Table 2). Body weight
slightly decreased by 3 and 6 months as well.
Analogue Insulin Doses
While daily BI doses were increased from base-
line to 6 months (from 34.5 ± 16.6 U to
41.0 ± 18.7 U), the daily prandial insulin doses
remained virtually the same (Table 2).
Safety Outcomes
Data was collected (based on patients’ self-re-
port) for confirmed non-severe hypoglycemic
events (blood glucose B 3.9 mmol/L and
\3.1 mmol/L), and for severe events when
patients needed third-party assistance. Com-
parison of the 3-month period before inclusion
(reference period) showed that the cumulative
incidence (proportion of patients with at least
one event) of both non-severe and severe events
decreased from 44.2% to 27.6% and from 8.3%
to 1.0%, respectively, although the length of
study observation (6 months) was twice as long
as the reference period before enrollment
(3 months). The event rates (events/patient-
year) were statistically significantly lower in
Table 1 continued
Variable Mean – SD or %
\ 8.0% and C 7.0% 58.7
C 8.0% 13.2
Not specified 25.4
SD standard deviation
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both the first and the second 3-month periods,
as well as during the whole study period com-
pared to the reference period (Table 3).
Comparison of Patient Subgroups
According to Switching Indications
On the basis of the indication for the switch to
analogue insulin, the 190 patients could be
categorized into subgroups switched because of
a single reason of having either inadequate
control (N = 152, uncontrolled subgroup) or
hypoglycemic events (N = 38, hypo subgroup),
of whom 128 and 32 patients had enough data
(baseline and follow-up HbA1c) to be included
in the subgroup efficacy analyses, respectively.
The baseline HbA1c level and the change in
HbA1c during the study showed considerable
differences according to switching indications.
Table 2 Changes in glycemic variables, HbA1c target value achievement ratio, body weight, and analogue insulin doses
Time Values, mean – SD or % Change from baseline, mean (95% CI)
HbA1c (%)
3 months 7.8 ± 1.1 - 1.0 (- 1.2; - 0.8)*
6 months 7.5 ± 1.1 - 1.4 (- 1.6; - 1.2)*
HbA1c target achievement (%) \ 7% \ 8%
Baseline 10.1 19.6 –
3 months 21.1 59.9 –
6 months 29.1 77.8 –
HbA1c individual target achievement (%)
6 months 37.6 –
Fasting blood glucose (mmol/L)
3 months 7.0 ± 1.6 - 2.5 (- 3.1; - 2.0)*
6 months 7.0 ± 2.1 - 2.6 (- 3.2; - 2.1)*
Postprandial blood glucose (mmol/L)
3 months 8.9 ± 1.9 - 3.0 (- 3.8; - 2.2)*
6 months 8.9 ± 2.5 - 3.0 (- 3.7; - 2.2)*
Body weight (kg)
3 months 93.7 ± 17.38 - 0.45 (- 1.33; 0.43)
6 months 93.2 ± 17.28 - 0.94 (- 2.18; 0.33)
Gla-300 daily doses (U)
3 months 38.3 ± 17.6 4.1 (3.0; 5.1)*
6 months 41.0 ± 18.7 6.6 (5.2; 7.9)*
Insulin glulisine daily doses (U)
3 months 39.4 ± 20.9 - 0.4 (- 1.6; 0.8)
6 months 39.9 ± 20.5 0.1 (- 1.3; 1.6)
*Statistically significantly different from baseline value, p\ 0.001
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Patients who were switched because of inade-
quate glycemic control at baseline had signifi-
cantly higher baseline HbA1c value and their
improvement of glycemic control was larger
compared to patients who were switched
because of hypoglycemia. The hypo subgroup
did not improve their glycemic control during
the study; however, on the basis of their base-
line HbA1c value, one would not have expected
them to do so (Fig. 1). Baseline dose of Gla-300
was higher in the uncontrolled subgroup but
the doses were increased significantly in both
subgroups—although to a considerably larger
extent in the uncontrolled subgroup (Fig. 2).
Changes in body weight were not significant in
any subgroup. Prandial insulin doses were
higher in the uncontrolled subgroup at baseline
and 6 months; however, changes were not sig-
nificant in any subgroup (Table 4).
The cumulative incidence and event rate of
all non-severe hypoglycemic events in the hypo
subgroup well reflected the respective switching
indication and were considerably higher
Table 3 Hypoglycemic events in the safety population statistically significantly different from period before enrollment
During 3 months before
enrollment
Between
Baseline and
3 months
3 and
6 months
Baseline and
6 months
Number (percent) of patients
with C 1 event and event rate
(events/patient-year) in the
safety population
Non-severe hypoglycemic events with blood glucose B 3.9 mmol/L
96 (44.2%)
9.76
29 (13.4%)
1.60*
53 (24.4%)
3.09*
60 (27.6%)
2.30*
Non-severe hypoglycemic events with blood glucose\ 3.1 mmol/L
No data 12 (5.6%)
0.42
20 (9.2%)
0.70
27 (12.4%)
0.55
Severe hypoglycemic events
18 (8.3%)
0.48
0 2 (1.0%)
0.08**
2 (1.0%)
0.04*
*p\ 0.001, **p = 0.001
Fig. 1 HbA1c values and changes in the subgroups of
patients designated according to the switch indication.
*p\ 0.001 (the data are in mean ± SD and mean change
(95% confidence interval) format)
Fig. 2 Gla-300 daily dose values and changes in the
subgroups of patients designated according to the switch
indication; *p = 0.001, **p\ 0.001 (the data are in
mean ± SD and mean change (95% confidence interval)
format)
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compared to the uncontrolled subgroup (100%
and 29.87 events/patient-year versus 17.8% and
2.74 events/patient-year, respectively). Remark-
ably the event rate (with B 3.9 mmol/L hypo-
glycemia cutoff) in the hypo subgroup
decreased to similar level compared to the event
rate in the uncontrolled subgroup despite hav-
ing a considerably higher rate at baseline before
the switching (29.87 and 3.05 versus 2.74 and
2.0 events/patient-year, respectively). The fre-
quency of non-severe hypoglycemic events with
blood glucose level below 3.1 mmol/L was sim-
ilar in both subgroups after analogue switch
(Table 5).
DISCUSSION
Insulin glargine 300 U/mL (Toujeo [Gla-300])
was launched in Hungary in 2016; however, its
100% reimbursement rate is conditioned to
complex payer requirements including inade-
quate glycemic control and/or occurrence of
non-severe or severe hypoglycemic events dur-
ing human BBT. Consequently, the patients
switched to analogue BBT can be categorized
according to the indication(s) for the switch. As
‘‘inadequate glycemic control’’ in the reim-
bursement rules is defined as HbA1c C 8%, this
value is an important cutoff point in daily
clinical practice. This reimbursement defined
target drives both the initiation of Gla-300 and
its sustained use beyond 12 months.
This non-interventional trial was designed to
investigate the effectiveness of Gla-300-based
BBT (administered together with insulin gluli-
sine, as mealtime insulin). The included
patients had to meet the Hungarian reimburse-
ment rules, i.e., were switched from human BBT
in all cases.
The included patients with the mean age of
60.9 years and mean diabetes duration of more
than 10 years at baseline well reflected the typ-
ical diabetes population physicians are faced
with during their daily practice. According to
the indication for switching, the study patients
were heterogenic: more than two-third were
switched because of inadequate glycemic con-
trol, 17.5% because of hypoglycemic events,
and the remaining with dual indication.
Table 4 Body weight and insulin glulisine dose changes in the subgroups of patients designated according to the switch
indication; statistically significant difference between the groups
Patients switched because of
inadequate glycemic control
(mean – SD)
Patients switched because of
hypoglycemic events
(mean – SD)
Between group
difference mean
(95% CI)
Body weight (kg)
Baseline 96.1 ± 18.82 91.9 ± 15.38 4.18 (- 2.92; 11.28)
6 months 94.8 ± 18.00 90.7 ± 14.22 4.09 (- 2.68; 10.85)
Change from baseline to
6 months, mean (95%
CI)
- 1.34 (- 3.12; 0.44) - 1.25 (- 2.89; 0.39)
Insulin glulisine daily doses (U)
Baseline 43.2 ± 22.99 33.1 ± 15.29 10.02 (1.56; 18.49)*
6 months 43.7 ± 21.76 31.9 ± 14.00 11.76 (3.77; 19.75)*
Change from baseline to
6 months, mean (95%
CI)
0.55 (- 1.31; 2.40) - 1.19 (- 4.99; 2.61)
*p = 0.004
474 Diabetes Ther (2020) 11:467–478
All glycemic variables collected during the
follow-up had decreased significantly by
3 months. Additional statistically significant
decrease between 3 and 6 months was detected
only in case of HbA1c. At the time of switching
from human to analogue regimen, the basal-
bolus ratio changed. With the analogue regi-
men, patients were prescribed higher basal and
lower mealtime insulin daily doses which might
be predominantly explained by the differences
of PK/PD characteristics of the bolus insulins
(human regular vs rapid-acting analogue). Dur-
ing the study, change in mean dose of the
prandial insulin can be considered as clinically
negligible, while the mean dose of BI was
increased significantly by about 12% and 19%
(by 3 and 6 months compared to the baseline
doses, respectively). Although there was a
modest body weight reduction during the
6-month follow-up, its magnitude is likely
clinically non-significant.
The external validity of observational studies
like Toujeo-6M is relatively high as a result of
the lack of strict inclusion and exclusion criteria
to involve patients. However, it is important to
put the results into context with outcomes
generated in randomized trials which investi-
gated similar patient populations using the
same therapeutic regimen under strict control.
Such comparisons can validate the observed
findings and vice versa. From the EDITION
program, the EDITION 1 trial [5] investigated
the same treatment regimen (BBT) similarly in
patients with T2DM. Both the baseline glycemic
control and the improvement during the
6-month follow-up in our study were higher
compared with the results from EDITION 1
(8.9% vs 8.2%, and - 1.4% vs - 0.8%, respec-
tively). It is important to highlight that the final
HbA1c values were comparable (7.5% and 7.3%
in our study and in EDITION 1, respectively)
which indicates that with treatment optimiza-
tion with Gla-300-based BBT, similar glycemic
control can be achieved in daily practice as in
strictly controlled protocol-driven randomized
controlled trials. Although the daily basal and
prandial insulin doses in EDITION 1 were con-
siderably higher than in our study, the differ-
ence can be attributed to the inclusion criteria
in EDITION 1 which only recruited patients
using at least 42 U of BI daily in the trial. Recent
results from DELIVER 2 [13] indicate a
Table 5 Hypoglycemic events (all and with blood glucose level below
3.1 mmol/L) in the group of patients switched because of inadequate
glycemic control or hypoglycemic events statistically significantly
different from the period before enrollment
Number (percent) of patients with ‡ 1 event
and event rate (events/patient-year)
During 3 months
before enrollment
Between
Baseline and
3 months
3 and
6 months
Baseline and
6 months
Non-severe hypoglycemic events with blood glucose B 3.9 mmol/L
Patients switched because of inadequate glycemic
control
27 (17.8%)
2.74
15 (9.9%)
1.47**
30 (19.7%)
2.60
34 (22.4%)
2.00*
Patients switched because of hypoglycemic
events
38 (100%)
29.87
6 (15.8%)
1.64**
12 (31.6%)
4.63**
14 (36.8%)
3.05**
Non-severe hypoglycemic events with blood glucose\ 3.1 mmol/L
Patients switched because of inadequate glycemic
control
No data 9 (5.9%)
0.52
9 (5.9%)
0.61
14 (9.2%)
0.56
Patients switched because of hypoglycemic
events
No data 2 (5.3%)
0.33
4 (10.5%)
0.68
6 (15.8%)
0.49
*p = 0.001, **p\ 0.001
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substantially smaller improvement of HbA1c
(- 0.5%) in patients with T2DM who were
switched to Gla-300-based insulin regimens
(basal-oral or basal-bolus) despite the similar
baseline HbA1c value (8.95%) compared to our
study. However, there is no information on the
dose titration after switching in DELIVER 2, so it
cannot be evaluated whether sufficient BI titra-
tion has been applied in the study. Further-
more, in DELIVER 2, patients were switched
from first-generation basal analogues (insulin
glargine U100/mL or insulin detemir) as
opposed to our study in which patients were
using human insulin-based BBT before
switching.
It is encouraging that by the end of the
6-month observational period, more than three-
quarters of the patients achieved the HbA1c
level below 8%, the threshold defined by the
payer to remain on analogue-based insulin reg-
imen with 100% reimbursement beyond
12 months’ use. Interestingly, individual target
values were achieved by much lower propor-
tions of the patients which suggests that inves-
tigators might have specified too ambitious
targets for this challenging patient population
with advanced T2DM.
Regarding hypoglycemia, cumulative inci-
dence and event rate of non-severe hypo-
glycemic events in our study (27.8% and
2.3 events/patient-year) were much lower than
those reported in EDITION 1 [5]—a phe-
nomenon that can probably be traced back to
the differences in the study design. The fre-
quency of patient–physician contact (in every
third month) did not allow as accurate adverse
event reports (reporting/recall bias) as the ran-
domized clinical trial did. However, as this
supposed bias in hypoglycemic event reporting
influenced the periods before and after the
inclusion in our study, the conclusion on the
beneficial hypoglycemia effects of analogue
switching should remain the same.
One of the most important findings in our
study relates to severe hypoglycemia, the type
of event for which reporting/recall bias is much
less relevant. Whilst more than 18 patients
(8.3%) reported such an event during the
3-month long pre-study period, only two
patients (1.0%) had an episode in the second
3 months of our study period. One should bear
in mind that our study population did not
exclude patients at high risk of hypoglycemia
(which is perhaps reflected in the relatively high
proportion of patients reporting such events
during the pre-study period being treated with
human insulin); thus, it is very encouraging to
see such marked reduction after switching. This
finding further confirms that severe hypo-
glycemia risk reduction might be achieved with
Gla-300-based insulin regimen in real-world
clinical practice, an important result first sug-
gested by DELIVER 2 which showed that Gla-
300 had fewer hypoglycemia events associated
with hospitalization or emergency department
encounters.
The beneficial effect on HbA1c levels was
even more prominent in the subgroup switched
because of inadequate glycemic control. At the
same time the improvement in HbA1c was not
significant in the hypo subgroup, a finding
which can be explained on the basis of the
already well-controlled baseline HbA1c level in
this group. Changes in body weight as well as
basal and prandial insulin dose in both groups
actually showed the same trend that could be
seen in the whole population analyses,
although in the uncontrolled subgroup both
the baseline insulin doses and the increase
during the study were considerably higher.
The baseline HbA1c values and hypo-
glycemic incidence/event rates well reflected
the switching indications in the respective
patient subgroups. The baseline HbA1c values
were significantly lower in the subgroup swit-
ched because of hypoglycemic events and did
not change significantly over the course of our
study, while hypoglycemic event rates
decreased to comparable level observed in those
switched because of inadequate control.
It is also important to highlight that in the
uncontrolled subgroup, the risk of low blood
sugar events did not increase parallel with the
considerable improvement of their glycemic
control. In fact, during the first 3 months of
Gla-300 treatment, the hypo risk was reduced
compared to the 3-month period before
switching. This observation (markedly reduced
hypoglycemia risk during first 3 months, a per-
iod when 62% of the basal up-titration
476 Diabetes Ther (2020) 11:467–478
occurred) was also detected in the entire study
population.
The most important limitations of this study
can be traced back to its non-interventional
design: (i) 17.5% of patients could not be
involved in the efficacy analyses because of
missing data, and (ii) the accuracy of the
detection of hypoglycemic event probably did
not meet the demands of a clinical trial as a
result of the typical 3-month patient–physician
contact frequency.
The most important strength of our non-in-
terventional study is that it demonstrates the
beneficial efficacy and safety effects of Gla-300
in patients either inadequately controlled or
who experienced a hypoglycemic event.
CONCLUSIONS
Gla-300-based analogue BBT in patients swit-
ched from human insulin BBT either because of
inadequate glycemic control or hypoglycemic
events proved to be efficient both in terms of
improved glycemic control (in the inadequately
controlled subgroup) and decreased risk of
hypoglycemia (in both subgroups).
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